Inhibition of the CCL2–CCR2 or CCL17/CCL22–CCR4 axis by specific antagonists of CCR2 or CCR4 clearly showed suppression of the migration ability of prostate cancer cells. Here, CCR2 is linked to prostate carcinoma.